Changes

Oral Diabetes Drugs

860 bytes added, 06:49, 6 August 2009

/* Contact Dolcera */

===Like this report?===

'''This is only a sample report with brief analysis'''

'''Dolcera can provide a comprehensive report customized to your needs'''

{|border="2" cellspacing="0" cellpadding="4" align="center" "

|style="background:lightgrey" align = "center" colspan = "3"|'''[mailto:info@dolcera.com Buy the customized report from Dolcera]'''

| align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services Patent Analytics Services]

|align = "center"| [http://www.dolcera.com/website_prod/services/business-research-services Market Research Services]

|align = "center"| [http://www.dolcera.com/website_prod/tools/patent-dashboard Purchase Patent Dashboard]

|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Landscape Services]

|align = "center"| [http://www.dolcera.com/website_prod/research-processes Dolcera Processes]

|align = "center"| [http://www.dolcera.com/website_prod/industries Industry Focus]

|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/patent-search/patent-landscapes Patent Search Services]

|align = "center"| [http://www.dolcera.com/website_prod/services/ip-patent-analytics-services/alerts-and-updates Patent Alerting Services]

|align = "center"| [http://www.dolcera.com/website_prod/tools Dolcera Tools]

===Prevalence===

The prevalence of diabetes( Both type I and type II ) in U.S. during the years 1980 to 2005, increased from 5.6 million to 15.8 million (Figure 4). Especially people aged from 65 to 74 had the highest prevalence compared to other age groups (Figure 5). The prevalence of the disease was similar in both men and women till the year 1998 but from 1999, the prevalence of the disease increased highly in men compared to females (Figure 6).

===Product pipeline===

[[Image:Roche.jpg|thumb|center|600px|]]

{|border="2" cellspacing="0" cellpadding="4" width="100%"

|align = "center" bgcolor = "#FFFF99" colspan = "3" |'''Product Pipeline'''

|align = "center"|Gastrin <nowiki>+</nowiki> DPP IV Inhibitor

|align = "center"|[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]

|align = "center"|2Preclinical

|colspan = "3"|'''Insulin sensitizer'''

~~|align = "center"|MBX 102~~

~~|align = "center"|[http://www.medicalnewstoday.com/articles/26017.php Metabolex]~~

~~|align = "center"|2~~

~~|align = "center"|MBX-2044~~

~~|align = "center"|[http://www.metabolex.com/pipeline.html Metabolex]~~

~~|align = "center"|1~~

|align = "center"|NCX 4016(Nitric Oxide donating derivative of Acetyl Salicylic acid)

|align = "center"|[http://www.nicox.com/update/NCX_4016.html NicOx]

~~|align = "center"|2~~

~~|align = "center"|Cholebine~~

~~|align = "center"|[http://www.m-pharma.co.jp/cgi-bin/pageview.cgi?pass=/e/develop/situation.html Mitsubishi Pharma]~~

|align = "center"|2

|align = "center"|NovoNorm®(repaglinide)/Metformin

|align = "center"|[http://www.novonordisk.com/science/pipeline/rd_pipeline.asp?showid=6 Novo Nordisk]

|align = "center"|3

|colspan = "3"|'''~~GLP 1 Analogue / Agonists~~Biguanides'''|-|-

|align = "center"|Gastrin <nowiki>+</nowiki> Metformin

|align = "center"|[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]

|align = "center"|1

|colspan = "3"|'''GLP 1 Analogue / Agonists''' GLP 1 Analogues have to be injected subcutaneously, Emisphere is working on an oral analogue

|align = "center"|Abiglutide (716155)

|align = "center"|[http://www.gsk.com/investors/product_pipeline/docs/pipeline.pdf glaxosmithkline]

|align = "center"|2

|align = "center"|TH0318

|colspan = "3"|'''Peroxisome Proliferator-Activated Receptor (PPAR) agonist/analogue'''

|align = "center"|CS-011 (Rivoglitazone)

|align = "center"|Sankyo

|align = "center"|2

|align = "center"|Metaglidasen(MBX 102)

|align = "center"|[http://www.medicalnewstoday.com/articles/26017.php Metabolex]

|align = "center"|2

|align = "center"|MBX-2044

|align = "center"|[http://www.metabolex.com/pipeline.html Metabolex]

|align = "center"|1

|align = "center"|[http://www.drugs.com/nda/muraglitazar_041223.html Bristol-Myers Squibb ]

|align = "center"|3

|align = "center"|R483

|align = "center"|[http://www.roche.com/pages/downloads/investor/pdf/praesentations/irp050504rdd14.pdf Roche]

|align = "center"|2

|align = "center"|PPM-204

|align = "center"|[http://www.wyeth.com/research/pipeline Wyeth], [http://www.invitrogen.com/downloads/Discovery_Inhibitor_Oncogenic_B-RAF.pdf Plexxikon]

|align = "center"|2

|align = "center"|[http://www.osip.com/PSN010 OSI]

|align = "center"| 

~~|colspan = "3"|'''β3-Adrenergic Receptor Agonist'''~~

~~|align = "center"|Solabegron (GW427353)~~

~~|align = "center"|[http://clinicaltrials.gov/ct/gui/show/NCT00401479?order=1 Glaxosmithkline]~~

~~|align = "center"|1~~

|align = "center"|[http://www.isispharm.com/product_pipeline.html Isis]

|align = "center"|1

|colspan = "3"|'''Antisense drug for Glucocorticoid Receptor (GCCR)'''

|align = "center"|189075

|align = "center"|[http://~~clinicaltrials~~www.~~gov~~gsk.com/ctinvestors/~~gui~~product_pipeline/~~show~~docs/~~NCT00401479?order=1~~ pipeline.pdf Glaxosmithkline]

|align = "center"|2

|align = "center"|2

|align = "center"|[http://www.theratech.com/en/products-therapeutic-peptides/pipeline.php Theratechnolgies]

|align = "center"| 

~~|colspan = "3"|'''Aldolase reductase inhibitor'''~~

~~|align = "center"|SNK-860, fidarestat~~

~~|align = "center"|[http://care.diabetesjournals.org/cgi/reprint/24/10/1776.pdf Sankyo]~~

~~|align = "center"|3~~

~~|colspan = "3"|'''Neurotrophin Enhancer'''~~

~~|align = "center"|MCC-257~~

~~|align = "center"|[http://www.m-pharma.co.jp/cgi-bin/pageview.cgi?pass=/e/develop/situation.html Mitsubishi Pharma]~~

~~|align = "center"|2~~

|align = "center"|TRX4

|align = "center"|[http://www.btgplc.com/PartneredDevelopment/240/TRX4.html BTG]

|align = "center"|2

|colspan = "3"|'''Selective inhibitor of fructose-1, 6-bisphosphatase (FBPase)'''

|align = "center"|CS-917

|align = "center"|[http://www.mbasis.com/pipeline/metabolic_disease.html Sankyo,Metabasis]

|align = "center"|2

|align = "center"|MB07803

|align = "center"|[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]

|align = "center"|2

|align = "center"|AMG 221

|align = "center"|[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen, Biovitrum]

|align = "center"|1

|align = "center"|IPLEX(Mecasermin rinfabate)

|align = "center"|Glen Allen

|align = "center"|Orphan Drug Status

~~|bgcolor = "#FFFF99" colspan = "3"|'''Miscellaneous'''~~

~~|align = "center"|MBX-8025~~

~~|align = "center"|[http://www.metabolex.com/MBX-8025.html Metabolex]~~

~~|align = "center"|2~~

|align = "center"|Nateglinide with insulin sensitizers

|~~align~~ colspan = "~~center~~3"|~~ |align~~ '''Islet Regeneration Factors'''

~~|align = "center"|869682~~

~~|align = "center"|[http://clinicaltrials.gov/ct/gui/show/NCT00291356?order=2 Glaxosmithkline]~~

~~|align = "center"|2~~

~~|align = "center"|815541~~

~~|align = "center"|[http://www.chartsbank.com/PipelineList.aspx Glaxosmithkline]~~

~~|align = "center"|1~~

|align = "center"|2

~~|align = "center"|CS-011 (Roviglitazone)~~

~~|align = "center"|Sankyo~~

~~|align = "center"|2~~

|align = "center"|~~ACOMPLIA®~~AMG 837 ( Rimonabant*Potentiates Glucose Dependent Insulin Secretion)|align = "center"|[http://enwww.~~sanofi-aventis~~amgen.com/rdscience/~~portfolio/p_rd_portfolio_metabo~~pipe_amg837.~~asp Sanofi Aventis~~html Amgen]|align = "center"|31

|align = "center"|R 1499

|align = "center"|[http://www.~~chartsbank~~roche.com/~~PipelineList~~pages/downloads/investor/pdf/praesentations/irp050504rdd14.~~aspx~~ pdf Roche]

|align = "center"|1

|align = "center"|R1438

|align = "center"|2

|align = "center"|R1440

|align = "center"|[http://www.~~chartsbank~~roche.com/~~PipelineList~~pages/downloads/investor/pdf/praesentations/irp050504rdd14.~~aspx~~ pdf Roche]

|align = "center"|2

|align = "center"|Neurocrine Biosciences

|align = "center"|2

~~|align = "center"|CS-917~~

~~|align = "center"|[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]~~

~~|align = "center"|2~~

~~|align = "center"|MB07803~~

~~|align = "center"|[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]~~

~~|align = "center"|2~~

~~|align = "center"|AMPK Project~~

~~|align = "center"|[http://www.mbasis.com/pipeline/index.html metabasis, Daiichi Sankyo]~~

~~|align = "center"|Discovery~~

|align = "center"|[http://www.merck.com/finance/pipeline.swf Merck]

|align = "center"|2

~~|align = "center"|Arxxant (ruboxistaurin)~~

~~|align = "center"|[http://investor.lilly.com/pipeline.cfm Eli Lilly]~~

~~|align = "center"|3~~

~~|align = "center"|11 B- HSD 1~~

~~|align = "center"|[http://www.biovitrum.com/upload/images/R&D/Projectportfolio_June_2007.pdf Biovitrum, Amgen]~~

~~|align = "center"|1~~

~~|align = "center"|Gastrin <nowiki>+</nowiki> Metformin~~

~~|align = "center"|[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]~~

~~|align = "center"|1~~

~~|align = "center"|AMG 837~~

~~|align = "center"|[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen]~~

~~|align = "center"|1~~

~~|align = "center"|Darbepoetin alfa~~

~~|align = "center"|[http://wwwext.amgen.com/science/pipe_AMG221.html Amgen]~~

~~|align = "center"|3~~

~~|align = "center"|Smylin(Amylin analogue)~~

~~|align = "center"|[http://www.amylin.com/pipeline/symlin.cfm Amylin]~~

~~|align = "center"|4~~

~~|align = "center"|Exenatide LAR~~

~~|align = "center"|[http://www.amylin.com/pipeline/symlin.cfm Amylin]~~

~~|align = "center"|2~~

~~|align = "center"|DG770 (beta cell regeneration factor)~~

~~|align = "center"|[http://www.develogen.com/en/prod_pipeline.php?hnav=2&tnav=0 Develogen AG]~~

~~|align = "center"|3~~

~~|align = "center"|E1 INT (Islet regeneration)~~

~~|align = "center"|[http://www.transitiontherapeutics.com/technology/index.php Transition Therapeutics]~~

~~|align = "center"|2~~

~~|align = "center"|Mecasermin rinfabate (IPLEX) (IGF 1 and 2)~~

~~|align = "center"|[http://www.fda.gov/cder/drug/InfoSheets/patient/mecasermin_rinfabatePIS.htm Insmed]~~

~~|align = "center"|Approved in 2005~~

~~|align = "center"|Orlistat (Xenical) (Lipase inhibitor)~~

~~|align = "center"|[http://www.xenical.com/xen_do_home.asp Roche]~~

~~|align = "center"| ~~

===Product Pathways===

[[Image:Product_map.jpg|thumb|center|900px| Product]]

[[Image:Product-map.jpg|thumb|center|900px| Product pipeline]]

==Intellectual Property==

* '''Search scope:''' US Granted US Applications EP-A EP-B WO JP (bibliographic data only) DE-C,B DE-A DE-T DE-U GB-A FR-A; '''English Title'''

* '''Years:''' '''Issue/Publication Date:''' >20051231

* '''Search String:''' (Diabetes OR diabetic) AND (treatment OR treating)

* '''Hits:''' 618/217 patents (with/with out family members)

* '''Date of search:''' 11 July 2007

===Top players and IPC classes===

[[Image:Diabetes- top players.jpeg|center|~~850~~ 800 px|]]

====IPC code definition====

===Geographical Distribution and Treatment Approaches===

[[Image:Diabetes -geographical.jpeg|center|~~850~~ 800 px|]]

===IP activity and Treatment Approaches===

* Decline in the IP activity during 2005 and 2006 is due 18 months publication delay of patent document.[[Image:Diabetes -year approach.jpeg|center|~~850~~ 800 px|]]

==Clinical Trials==

* [http://www.conferencealerts.com/seeconf.mv?q=ca13a3h0 7th International Diabetes Federation Western Pacific Region Congress] at Wellington, New Zealand on 30 Mar 2008.

* [http://debussy.hon.ch/cgi-bin/confevent?aff2+CONF07692+Diabetes_Mellitus 1st International Conference on Advanced Technologies & Treatments for Diabetes] at Czech Republic during 27 Feb to 01 Mar 2008.

* [http://www.goingtomeet.com/conventions/details/5301 Discovery Strategies Conference: Modeling Human Metabolic Syndrome and Type 2 Diabetes in Rodents] at Us US during Aug-05-2007.

* [http://www.goingtomeet.com/conventions/details/15113 7th International Conference for Clinical Endocrinology,Diabetes and Infertility] at Egypt during Sep-06-2007.

* [http://www.diabetes.ca/section_professionals/confindex.asp CDA/CSEM Professional Conference and Annual Meetings] at British Columbia during October 24-27, 2007.

==== Conference highlights for Oral Hypoglycemic Agents ====

# [[~~Diabetes~~Oral_Diabetes_Drugs#Products:_Oral_Hypoglycemic_Agents|Oral hypoglecemic agents]] and their role in diabetes treatment. The focus was the recent meta analysis published in [http://content.nejm.org/cgi/content/full/356/24/2457?ijkey=9288cc5edfcb35c1e7f1bd5d974d1169d64cea0b NEJM], showing increase CV mortality with Rosiglitazone. The panel consensus was that while awaiting more safety data, for now those patients who are tolerating Rosiglitazone should continue taking them, whereas newly diagnosed patients should try alternative treatment. Also all PPAR agonists should be treated as distinct entities rather than having class effect.# 12 different [[~~Diabetes~~Oral_Diabetes_Drugs#Products:_Oral_Hypoglycemic_Agents ~~DPP–IV inhibitors~~| diabetes products]] are in various stages of development, and there were about 55 abstracts talking about DPP–IV inhibitors. They are especially useful for:

#* The elderly

#* Those with renal insufficiency

#[http://www.amylin.com/pipeline/symlin.cfm Amyline] analogue (Pramlinitide) was combined with Insulin for treatment of Type 2 DM and results were favorable.

# Continuous glucose monitoring using implanted glucose sensors is a step forward in evolving technology. Yet it is still very expensive and best for highly trained patients on intensive insulin therapy.

==Like this report?==